What diseases does Retifanlimab (Zynyz) primarily treat?

Retifanlimab (trade name Zynyz) is a new immune checkpoint inhibitor mainly used to treat squamous cell carcinoma of the anal canal (SCAC). This cancer is a rare malignant tumor that often occurs in the squamous epithelial cells of the anal area and is often associated with infection with the human papillomavirus (HPV). Since anal canal squamous cell carcinoma often has no obvious symptoms in the early stages and is often locally advanced or metastatic when diagnosed, it is difficult to treat. The emergence of Retifanlimab has brought new treatment hope to these patients.

The indications of Retifanlimab include two major aspects: first, it is used in combination with the chemotherapy drugs carboplatin and paclitaxel for initially treated patients with unresectable locally recurrent or metastatic anal squamous cell carcinoma. Clinical studies have shown that this combination regimen can effectively extend the progression-free survival of patients and improve the treatment response rate. Secondly, Retifanlimab is also approved as monotherapy for patients with locally recurrent or metastatic anal squamous cell carcinoma who are resistant to platinum-based chemotherapy or who are unable to tolerate such chemotherapy.

Immune checkpoint inhibitors recognize and attack tumor cells by activating the patient's own immune system. Retifanlimab blocks the binding of PD-1 protein and its ligands, thereby lifting the immunosuppressive state and enhancing the killing effect of immune cells on tumors. Therefore, unlike traditional chemotherapy, it targets the immune mechanism of the tumor microenvironment and can bring about long-lasting and more targeted anti-cancer effects.

Overall, Retifanlimab is of great significance in the treatment of anal canal squamous cell carcinoma, especially in cases where patients are inoperable and have limited response to traditional chemotherapy. Its clinical application enriches the treatment methods, improves the prognosis of patients, and becomes an innovative option in the treatment of anal canal squamous cell carcinoma. In the future, as more research is conducted, Retifanlimab may be expanded to the treatment of other related cancers.

References:

https://www.fda.gov/drugs/resources-information-approved-drugs